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Abstract 
       
          This study was carried-out in Khartoum State to evaluate the 
seroprevalence of hepatitis C virus infection in the various group studied. 
Blood samples were stochastically collected from 295 blood donors, 20 
multitransfused individuals and 65 haemodialysis patients. 
            Immunochromotagrophy technique (ICT) and indirect HCV ELISA 
test using recombinant antigens were used to measure HCV- antibodies so that 
a comparison can be done on their sensitivity and specificity as well as to 
correlate the changes the rise in liver enzymes values.  
      Only two (0.52%) blood donors were found positive for HCV – antibodies 
by ICT, whereas three (0.78%) blood donors were positive by HCV ELISA 
test. In multitransfused patients only one (0.21%) patients was found positive 
by both techniques. In the haemodialysis group eight (2.1%) patients were 
positive for HCV- antibodies by ICT and nine (2.3%) patients were positive 
by ELISA test. 
       In the various groups studied (totaling 380) ELISA was able to detected 
the presence of HCV- antibodies in 13 (3.4%) individual but by using ICT 
only eleven (2.89%) HCV- antibodies positive individuals were detected. 
However this difference was not statistically significant (T. test value less than 
0.5). Therefore, both tests are reliable for screening HCV – antibodies in 
patients as far as a recombinant antigens were employed in both test to ensure 
specificity.  
        Liver enzymes values were estimated in all HCV – antibodies positive 
samples. Samples obtained from blood donors and multitransfused individuals 
showed normal levels of ALT ≤ 31U/L, AST ≤ 40U/L and ALP ≤ 53-128 
U/L, when tested at 37oC. But samples obtained from haemodialysis patients 
showed an elevated liver enzymes level: ALT (96.46 ± 58.96), AST (111 ± 
66.52) and ALP (160.15 ± 36.21) levels. This might reflected the chronicity of 
HCV infection in these patients. 
       In this study haemodialysis machine and probably surgical instruments 
represent a risk factor, but sexual practices and tattooing may not a role in 
predisposition to the disease in the various groups studied.   
           
 
 
 
 
 
 
 
 
 
 ﻤﻠﺨﺹ ﺍﻟﺭﺴﺎﻟﻪ
 ﻤﻌﻴﺎﺭ ﺍﻻﺼﺎﺒﻪ ﺒﻔﻴﺭﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ   ﻭﻻﻴﺔ ﺍﻟﺨﺭﻁﻭﻡ ﻟﻘﻴﺎﺱ           ﺃﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﻪ ﻓﻲ
ﺘﻡ ﺠﻤﻊ ﻋﻴﻨﺎﺕ ﻤﻥ ﺍﻟﺩﻡ ﻋﺸﻭﺍﺌﻴﺎ ﻤﻥ ﻤﺠﻤﻭﻋﺎﺕ . ﻓﻲ ﻤﺠﻤﻭﻋﺎﺕ ﺒﺸﺭﻴﻪ ﻤﺨﺘﻠﻔﻪ( ﺝ)ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ ﻨﻭﻉ 
ﺴﻴل ﺍﻟﺩﻤﻭﻱ  ﻋﻴﻨﺔ ﻤﻥ ﻤﺭﻀﻰ ﺍﻟﻐ56 ﻋﻴﻨﺔ ﺩﻡ ﻤﻥ ﺍﻷﺸﺨﺎﺹ ﺍﻟﻤﺘﺒﺭﻋﻴﻥ ﺒﺎﻟﺩﻡ ﻭ592: ﻤﺨﺘﻠﻔﻪ ﺘﺸﻤل
ﺃﺠﺭﻱ ﺍﻻﺨﺘﺒﺎﺭ ﺒﻭﺍﺴﻁﺔ ﺘﻘﻨﻴﺔ ﺍﻟﻜﺭﻭﻤﺎﺘﻭﻏﺭﺍﻓﻲ . ﻋﻴﻨﺔ ﻤﻥ ﺃﺸﺨﺎﺹ ﺘﻡ ﻟﻬﻡ ﻨﻘل ﺩﻡ ﺃﻜﺜﺭ ﻤﻥ ﻤﺭﻩ02ﻭ 
ﺍﻟﻤﻤﻨﻊ ﻭﺍﻻﻟﻴﺯﺍ ﻏﻴﺭ ﺍﻟﻤﺒﺎﺸﺭ ﻟﻠﻤﻘﺎﺭﻨﻪ ﺒﻴﻨﻬﻤﺎ ﻤﻥ ﺤﻴﺙ ﺍﻟﺤﺴﺎﺴﻴﻪ ﻭ ﺍﻟﺨﺼﻭﺼﻴﻪ ﻭﺃﻴﻀﺎ ﺘﻡ ﺍﻟﻜﺸﻑ ﻋﻥ 
ﻯ ﺍﻨﺯﻴﻤﺎﺕ ﺍﻟﻜﺒﺩ ﻤﻊ ﻤﺴﺘﻭﻯ ﺍﻨﺯﻴﻤﺎﺕ ﺍﻟﻜﺒﺩ ﻓﻲ ﺍﻟﻌﻴﻨﺎﺕ ﺍﻟﻤﻭﺠﺒﻪ ﻟﻤﻌﺭﻓﺔ ﺍﻟﻌﻼﻗﻪ ﺒﻴﻥ ﺍﺭﺘﻔﺎﻉ ﻤﺴﺘﻭ
  .ﻭﺠﻭﺩ ﺍﻷﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﻩ 
ﻤﻥ ﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺘﺒﺭﻋﻴﻥ ﻤﻭﺠﺒﻪ ﺒﺎﺴﺘﻌﻤﺎل %( 25.0)        ﺒﻌﺩ ﺍﺠﺭﺍﺀ ﺍﻻﺨﺘﺒﺎﺭﺍﺕ ﻭﺠﺩ ﺍﻥ ﻋﻴﻨﺘﺎﻥ 
ﻤﻭﺠﺒﻪ ﻤﻥ ﻨﻔﺱ ﺍﻟﻤﺠﻤﻭﻋﻪ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﻻﻟﻴﺯﺍ %( 87.0)ﺘﻘﻨﻴﺔ ﺍﻟﻜﺭﻭﻤﺎﺘﻭﻏﺭﺍﻓﻲ ﺍﻟﻤﻤﻨﻊ ﻭ ﺜﻼﺜﻪ ﻋﻴﻨﺎﺕ 
ﻥ ﺘﻡ ﻟﻬﻡ ﻨﻘل ﺩﻡ ﺃﻜﺜﺭ ﻤﻥ ﻤﺭﻩ ﻭﺠﺩﺕ ﻋﻴﻨﻪ ﻭﺍﺤﺩﻩ ﻏﻴﺭ ﺍﻟﻤﺒﺎﺸﺭ ،ﺃﻤﺎ ﻓﻲ ﻤﺠﻤﻭﻋﺔ ﺍﻻﺸﺨﺎﺹ ﺍﻟﺫﻴ
ﺃﻤﺎ ﻓﻲ ﻤﺠﻤﻭﻋﺔ ﻤﺭﻀﻰ ﺍﻟﻐﺴﻴل ﺍﻟﺩﻤﻭﻱ ﻭﺠﺩﺕ ﺜﻤﺎﻨﻴﻪ . ﻤﻭﺠﺒﻪ ﺒﺎﺴﺘﺤﺩﺍﻡ ﺍﻟﺘﻘﻨﻴﺘﻴﻥ%( 12.0)
ﺒﺎﺴﺘﻌﻤﺎل ﺍﺨﺘﺒﺎﺭ ﺍﻟﻜﺭﻭﻤﺎﺘﻭﻏﺭﺍﻓﻲ ( ﺝ)ﻋﻴﻨﺎﺕ ﻤﻭﺠﺒﻪ ﻟﻤﺭﺽ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ ﻨﻭﻉ %( 3.2)
ﺒﺎﺴﺘﻌﻤﺎل ( ﺝ)ﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ ﻨﻭﻉ ﻤﻭﺠﺒﻪ ﻟﻤﺭﺽ ﺍ%( 3.2)ﺍﻟﻤﻤﻨﻊ ﺒﻴﻨﻤﺎ ﻭﺠﺩﺕ ﺘﺴﻊ ﻋﻴﻨﺎﺕ
  .ﺍﺨﺘﺒﺎﺭ ﺍﻻﻟﻴﺯﺍ ﺍﻟﻐﻴﺭ ﻤﺒﺎﺸﺭ
ﻋﻴﻨﻪ %( 4.3 )31ﻋﻴﻨﻪ ﺘﻡ ﺍﻟﻜﺸﻑ ﻋﻥ( 083)        ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﻤﺨﺘﻠﻔﻪ ﺍﻟﺘﻲ ﺘﻤﺕ ﺩﺭﺍﺴﺘﻬﺎ
ﻋﻴﻨﻪ ﻤﻭﺠﺒﻪ ﺒﻭﺍﺴﻁﺔ ﺘﻘﻨﻴﺔ %( 98.2 )11ﻤﻭﺠﺒﻪ ﺒﻭﺍﺴﻁﺔ ﺍﺨﺘﺒﺎﺭ ﺍﻻﻟﻴﺯﺍ ﺍﻟﻐﻴﺭ ﻤﺒﺎﺸﺭ ﻭ
ﺍ ﺍﻟﻔﺭﻕ ﻟﻴﺱ ﻤﻌﺘﺒﺭﺍ ﻋﻨﺩ ﺘﺤﻠﻴل ﺍﻟﺒﻴﺎﻨﺎﺕ ﺍﺤﺼﺎﺌﻴﺎ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺠﺩﻭل ﺍﻟﻜﺭﻭﻤﺎﺘﻭﻏﺭﺍﻓﻲ ﺍﻟﻤﻤﻨﻊ، ﻭﺠﺩ ﻫﺫ
ﻭﺒﺎﻟﺘﺎﻟﻲ ﻓﺎﻥ ﻜﻼ ﺍﻻﺨﺘﺒﺎﺭﻴﻥ ﻴﻤﻜﻥ ﺍﻻﻋﺘﻤﺎﺩ ﻋﻠﻴﻬﻤﺎ ﻓﻲ ﺍﻟﻜﺸﻑ ﻋﻥ ﺍﻻﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﻩ ﻻﻟﺘﻬﺎﺏ ( T)
  ﺨﺎﺼﺔ ﺍﺫﺍ ﺍﺴﺘﻌﻤل ﺍﻟﻤﺴﺘﻀﺩ ﺍﻟﻤﺅﺸﺏ ﻓﻴﻬﺎ   ( ﺝ)ﺍﻟﻜﺒﺩ ﺍﻟﻔﻴﺭﻭﺴﻲ 
ﺹ ﺍﻟﻤﺼﺎﺒﻴﻥ ﻜﺎﻨﺕ ﺒﻤﻌﺩل ﻁﺒﻴﻌﻲ ﻓﻲ       ﻭﻋﻨﺩ ﺍﻟﻜﺸﻑ ﻋﻥ ﻤﺴﺘﻭﻯ ﺍﻨﺯﻴﻤﺎﺕ ﺍﻟﻜﺒﺩ ﻓﻲ ﺍﻷﺸﺨﺎ
ﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺘﺒﺭﻋﻴﻥ ﺒﺎﻟﺩﻡ ﻭ ﺍﻟﺫﻴﻥ ﺘﻡ ﻟﻬﻡ ﻨﻘل ﺩﻡ ﺃﻜﺜﺭ ﻤﻥ ﻤﺭﻩ، ﺃﻤﺎ ﻤﺭﻀﻰ ﺍﻟﻐﺴﻴل ﺍﻟﺩﻤﻭﻱ ﻓﻜﻠﻬﻡ 
  .ﺴﺠﻠﻭﺍ ﺍﺭﺘﻔﺎﻉ ﻓﻲ ﻤﺴﺘﻭﻯ ﺍﻨﺯﻴﻤﺎﺕ ﺍﻟﻜﺒﺩ
       ﺘﺨﻠﺹ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﻪ ﺍﻟﻲ ﺍﻥ ﻤﺎﻜﻴﻨﺔ ﺍﻟﻐﺴﻴل ﺍﻟﺩﻤﻭﻱ ﻭ ﺍﺩﻭﺍﺕ ﺍﻟﺠﺭﺍﺤﻪ ﺭﺒﻤﺎ ﺘﻤﺜل ﻋﻭﺍﻤل ﺫﻭ 
ﻟﻤﺭﺽ،ﺒﻴﻨﻤﺎ ﺍﻟﻤﻤﺎﺭﺴﻪ ﺍﻟﺠﻨﺴﻴﻪ ﻭ ﺍﻟﻭﺸﻡ ﺭﺒﻤﺎ ﻻ ﻴﻠﻌﺒﺎ ﺩﻭﺭﺍ ﻓﻲ ﺍﻨﺘﺸﺎﺭ ﺍﻟﻤﺭﺽ ﻓﻲ ﺨﻁﻭﺭﻩ ﻓﻲ ﻨﻘل ﺍ
  .       ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﻤﺨﺘﻠﻔﻪ ﺍﻟﺘﻲ ﺘﻤﺕ ﺩﺭﺍﺴﺘﻬﺎ
 
Chapter One 
 
1-1 Introduction: 
Hepatitis C virus is single stranded RNA (ssRNA) virus of the family 
flaviviridae (Murphy et al., 1999). HCV was identified in 1989 and was found 
to be responsible for 70-90% of post-transfusion hepatitis in all countries 
where blood was tested for HBV markers (Kau et al., 1989). 
 Humans seem to be the sole source of infection and inoculation with 
blood and blood products is the most recognized mode of transmission (Aach 
et al., 1991). Most of acute infections are asymptomatic with about   10 % of 
patients having mild flue-like illness with jaundice and a rise in serum 
aminotransferase (Garson et al., 1990).         
Hepatitis C has been referred to as a “silent epidemic”, since it usually 
progresses slowly over many years. Most people who are infected with 
hepatitis are not aware of any noticeable symptoms. In fact by the time 
symptoms appear, the virus may have probably begun to damage the liver. 
Furthermore, HCV caused over 90% of post-transfusion hepatitis before 
serological test allowed the screening of blood donors, and accounted for the 
high incidence of chronic hepatitis in patients with haemophilia (Cha et al., 
1999). The lack of convenient culture system for HCV implies the use of 
molecular biology to assess viremia. Direct hybridization of serum samples is 
possible but is hampered by the low virus concentration in most patients. 
Amplification of viral nucleic acid by the polymerase chain reaction (PCR) 
provides a highly sensitive and antigen-antibody-independent method to 
detect ongoing viral infection. Although a positive PCR assay is not absolute 
proof of HCV viremia, it strongly suggests active virus production within the 
body (Cha et al., 1999; Choo et al., 1989; Garson et al., 1990; Inchaups et al., 
1991 and Okamoto et al., 1990).   
Until sensitive and accurate test become available, diagnosis of HCV is 
frequently done by exclusion of a high risk individual with negative markers 
for HAV and HBV as well as on clinical and epidemiologic features of the 
individual patients (Knipe et al., 2001). HCV RNA can be detected one or two 
weeks after infection and anti-HCV antibodies are usually positive six weeks 
from infection (Okamoto et al., 1990). HCV RNA genome is approximately 
9.5kb in length encoding a polyprotein product consisting of structural and 
non structural viral proteins. The HCV contain several antigens giving rise to 
antibodies in infected individual and these are used for diagnosis (Choo et al., 
1994). 
 Previously diagnosis depended on identifying antibodies to a single 
viral antigen (C-100) but this test gave false positive reactions, especially in 
conditions such as autoimmune hepatitis associated with hyperglobulinaemia 
false negative reactions also occur. Therefore current laboratory diagnosis 
depends on identifying antibodies to several viral antigens. These tests 
generally identify antibodies in blood during the first three months of illness. 
Antigens from nucleocapsid regions have been used to develop ELISA, 
the current assay ELISA-3 (3rd generation ELISA) incorporate nonstructural 
recombinant antigens three, four and five (NS3, NS4 and NS5) regions. 
Patient infected with HCV develop antibodies to various structural and 
nonstructural viral proteins. Sensitive methods or tests are also now available 
for the detection of viral nucleic acid (Inchaupse et al., 1991). For instance 
RT.PCR can show HCV-RNA in the blood but it is only used when 
serological tests gave equivocal results as were as and in selecting for, and 
measuring response to therapy.  
 
 
  
 
 
 
 
 
The objectives of the present study were as follows: 
1- To determine the prevalence of HCV antibodies in blood donors, multi-
transfused and haemodialysis patients. 
2- To compare the specificity and sensitivity between (rapid one test) 
immunochromatogrophy test and enzyme linked immunosorbentassay 
(ELISA). 
3- Estimation of the liver enzymes levels for assessment of the liver 
functions in HCV infected individuals. 
4- To reduce post-transfusion hepatitis C by screening blood donors. 
 
 
 
 
 
 
 
 
 
 
 
Chapter Two 
Literature Review 
 
2-1 Definition: 
Hepatitis is a systemic disease primarily involving the liver (Jawetz et 
al., 1998).This infection or inflammation is the response of tissue injuries that 
show swelling, redness, increase in temperature and loss of function (Weir 
and Steward et al., 1997). Hepatitis may be acute or chronic infection (Soni et 
al., 1995). Hepatitis viruses produce acute inflammation of the liver, resulting 
in a clinical illness characterized by fever and gastrointestinal symptoms such 
as nausea, vomiting and jaundice, regardless of the virus type involved 
(Jawetz et al., 1998). 
2-2 Infectious Agents: 
Hepatitis can be caused by a variety of organisms and toxins (William 
et al., 2001). Accordingly hepatitis may be classified as infectious and non-
infectious hepatitis. Non-infectious hepatitis is caused by alcohol, toxins, and 
chemicals or by drugs, whereas infectious hepatitis is caused by different 
microbial agents. However, viruses are considered the most common 
causative agents of infectious hepatitis (Jawetz et al., 1998). 
Most cases of acute viral hepatitis seen in children and adults are 
caused by one of the following agents: in viral hepatitis type A, B, C, D, E and 
G (Albert et al., 1991).Table (1) and (2) where the types and characterization 
of viral hepatitis were shown respectively. Secondary hepatitis due to other 
viruses includes yellow fever virus, Marburg virus, and Ebola virus. Also 
acute hepatitis may occur as an unusual complication of infection by a number 
of non-hepatotropic viruses such as Rubella virus, herpes simplex virus, 
Episton-Barr virus and cytomegalovirus virus (Mowat et al., 2000). 
2-3 Viral Hepatitis: 
2-3-1 Hepatitis Type B virus (HBV): 
HBV is the cause of serum hepatitis (Jawetz et al., 1998). And is a 
leading cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma 
(HCC) (William et al., 2001). It is classified as a hepadnavirus, genus ortho- 
hepadna virus (Jawetz et al., 1998). HBV virion DNA is a relaxed circular, 
partially duplex species of 3.2kb, have an envelope (Knipe et al., 2001). HBV 
infection results from parenteral exposure to virus-containing blood or blood 
products or from sexual contact with an infected host (table 2). HBV is 
transmitted mainly by blood and known as serum hepatitis or long-incubation 
hepatitis (Hersh et al., 1971). However breast milk does not appear to play a 
role in transmission (Beasley et al., 1975). Infectious HBV is present in all 
body fluids of an infected individual; therefore, blood, semen and saliva serve 
as source of infection (William, et al., 2001). Some infected patients never 
recover completely and are called carriers. Treatment is not very effective, so 
prevention is crucial. Recombinant vaccines provide protection in 90-95% of 
healthy persons; it can be given safety to infants, children and adult in three 
doses (Mulley et al., 1982). 
2-3-2 Hepatitis Type A virus (HAV): 
HAV is picornavirus, with a linear, single-stranded, positive-sense 
RNA genome, with a size of 7.5 kb and is a non enveloped virus (William  et 
al., 2001).There is no antigenic cross-reactivity with HBV or with other 
hepatitis viruses (Jawetz et al., 1998). Virion RNA acts as mRNA and is 
translated into a polyproteins, which is then cleaved to individual proteins 
(Murphy et al., 1999). The virus is transmitted by oro-faecal routes, or 
ingestion of contaminated food or water (Snydman., et al., 1981), and have 
short incubation period ranging between 20-50 days (Hollinger and Ticehurst, 
1996).Formalin-inactivated whole viruses vaccine is available (William et al., 
2001). 
2-3-3 Hepatitis Type D (HDV):  
HDV caused by a delta virus is found in nature only as a result of co-infection 
with HBV (William et al., 2001). HDV is a defective virus, which requires 
HBV to serve as a helper virus; it is often associated with severe form of 
hepatitis in HBs Ag (hepatitis B surface antigen) positive patients (Jawetz et 
al., 1998). HDV has a circular, single stranded negative-sense RNA genome 
(William et al., 2001). It is transmitted by blood and blood products (Table 2) 
and it does not appear to be transmitted sexually (William et al., 2001). 
No loss of activity occurred following treatment with ethylene 
diaminetetra-acetic acid (EDTA), but partial or complete loss of activity was 
detected after treatment with alkali, thiocyanate, trichloroacetic acid and 
proteolytic enzymes (Jawetz et al., 1998). Infection acquired at the same time 
with HBV is called co-infection (Hoofnagle 1989). 
2-3-4 Hepatitis Type E (HEV): 
Hepatitis type E caused by a virus that belong to the family 
caliciviridae, it has formerly been identified as non-A, non-B agent. It is 
different from the other hepatitis virus that it is transmitted enterically and 
occurs in epidemic form in developing countries (Jawetz et al., 1998). It is 
virion is non enveloped, with icosahedral symmetry. The genome is composed 
of a single molecule of linear positive-sense, single stranded RNA that 
replicate in the cytoplasm (Murphy et al., 1999). HEV is a major cause of the 
enterically transmitted, water-borne hepatitis in developing countries.   No 
antiviral treatment or vaccine is currently available (William et al., 2001)  
2-3-5 Hepatitis Type G (HGV): 
Hepatitis type G caused by a new member of the flaviviridae which is 
transmitted by blood and blood products (Karayiannis et al., 1997). It is 
associated with morbidity and mortality among pregnant women. Hepatitis G 
virus has been isolated but has not been well characterized. 2-3-6 Hepatitis 
Type C (HCV): 
The HCV was first identified and described in 1989 (Choo et al., 1989). 
Hepatitis C virus (HCV) has been known to be a major a etiologic agent of 
post-transfusion as well as sporadic non-A, non-B hepatitis (NANBH) world 
wide, Aach et al., 1991 estimated that 91% of NANBH transfusion hepatitis is 
caused by hepatitis C virus. Until recently, diagnosis of this entity was done 
by exclusion of HAV, HBV, cytomegalovirus and Epstein-Barr virus in a 
patient who presented clinical evidence of hepatitis. The discovery of HCV 
and the molecular cloning of its genome and production of                   a 
recombinant antigen permitted the recent development of an enzyme 
immunoassay for detection of antibodies to HCV (Choo et al., 1989). Patient 
with or without clinical evidence of liver disease can transmit this disease, 
although the risk is significantly greater when the donor has alanine amino 
transferase abnormalities (Hollinger et al., 1989). 
  
 
 
 Table (1):  Types of viral hepatitis. (Albert  et al., 1991). 
  
Agent 
Preferred 
terminology 
Equivalent terminology  
Hepatitis A virus HAV 
Infectious hepatitis  
Epidemic jaundice  
Short incubation hepatitis  
Hepatitis B virus HBV 
Serum or transfusion hepatitis  
Long incubation hepatitis 
Homologous serum jaundice 
Hepatitis C virus HCV 
Parenterally transmitted non-
A, non-B hepatitis   
Hepatitis D virus HDV Delta hepatitis  
Hepatitis E virus HEV 
Enterically transmitted non-A, 
non-B hepatitis 
 
 
 
 
 
 
 
 
 
 
 
Table (2): Characteristics of hepatitis viruses (Jawetz, 1998). 
 
Virus Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E 
Family Picornaviridae Hepadnaviridae Flaviviridae Unclassified Caliciviridae 
Genus Hepatovirus Orthohepadna- 
virus 
Unnamed Deltavirus Unnamed 
Virion 27 nm, icosahedral 42 nm, 
spherical 
30-60 nm, 
spherical 
35nm, spherical 30-32nm, 
icosahedral  
Envelope No Yes (HBsAg) Yes Yes (HBsAg) No 
Genome ssRNA  dsDNA  ssRNA  ssRNA  ssRNA  
Genome size 7.5 kb 3.2 kb 9.5 kb 1.7 kb 7.6 kb 
Stability Heat- and acid-
stable 
Acid-sensitive Ether-
sensitive, 
acid-
sensitive 
Acid-sensitive Heat-stable 
Transmission Fecal-oral Parenteral  Parenteral Parenteral Fecal-oral 
Prevalence  High High Moderate Low, regional Regional 
Fulminant 
disease 
Rare Rare Rare Frequent In pregnancy 
Chronic 
disease 
Never  Often Often Often Never 
Oncogenic No Yes Yes ? No 
 
Hepatitis G virus has been isolated but has not been well characterized 
enough to be included here. 
 
 
 
 
In 1990 a test for the detection of hepatitis antibody (Anti-HCV) 
become commercially available to help in identifying individuals exposed to 
HCV infection (Chaudhary and Mac Lean 1993; Lavanchy et al., 1994 and 
Powlotsky et al., 1998). 
2-4 Classification of HCV: 
          HCV has a similar genomic organization and polyprotein hydro-
phobicity profile as the pestiviruses and flaviviruses (Choo et al., 1991) and 
has been classified as a separate genus in the family Flaviviridae (Francki et 
al., 1991) (Figure 1).HCV is the sole member of the Hepacivirus genus 
(Jawetz et al., 1998). 
The family Flaviviridae comprises three genera (flavivirus, pestivirus 
and hepacivirus), the members of which, although similar in genomic and 
physicochemical properties, are biologically quite different (Murply et al., 
1999). Most members are transmitted by blood-sucking arthropods, but HCV 
has no known vector (Jawetz et al., 1998). 
2-5 Nomenclature and Genotypes: 
 On basis of the sequence diversity, HCV is now classified into at least six (1 
to 6) major genotypes, each of which can be further divided into a number of 
subtype. It has been shown that antibodies to the core regions can be used to 
distinguish between some HCV genotypes due to variation in the amino acid  
sequence (Simmonds et al., 1993). There are other methods used in 
genotyping of HCV that include: Restriction fragment length polymorphism 
(RFLP) (Simmonds et al., 1993), reverse dot blot hybridization analysis 
(Stuyver et al., 1996) and Nested polymerase chain reaction (PCR) (Okamato 
et al., 1992). Nonetheless, PCR amplification and sequence analysis is the 
most reliable methods for determining genotype differences of HCV isolates 
(Choo et al., 1989). 
 2-6 Genome Structure of HCV: 
Low levels of virus in plasma samples and problems of in vitro cultivation 
have made visualization of this virus difficult; however, virus-like particles 
have been identified using electron microscopy (Shimizu., et al., 1996). The 
genome of HCV was sequenced and characterized long before these virus-like 
particles were described. It was shown early, that HCV is inactivated by 
chloroform (Feinstone et al., 1983), indicating that the particles are enveloped, 
and it was shown through filtration that the diameter is between (30-60nm) 
(Helf. et al., 1987). The HCV genome was isolated by screening 
complementary DNA (cDNA) expressions libraries made from RNA and 
DNA obtained from chimpanzees infected with serum from a patient with 
post-transfusion non-A, non-B hepatitis (Choo et al., 1989).   
RNA          DNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (1): Classification of major viral agents causing hepatitis. 
Note: HDV is a defective virus and is classified in it is own “floating” 
genus. (William et al. 2001) 
Single-Stranded Double-stranded 
Enveloped Positive strand 
Hepadnaviridae 
EnvelopedNon-enveloped 
Icosahedral 
Icosahedral 
Flaviviridae 
Hepatitis C
Caliciviridae
          Hepatitis E
Picornaviridae
Hepatitis A
Hepatitis D
Hepatitis B 
The genome consist of a single molecule of linear positive-sense, single-
stranded RNA, 9.5kb in size. Genomic RNA is infectious. The viral genome 
contains a single long open reading frame encoding about 10 proteins which 
are formed and cleaved by posttranslational processing. (Figure 2). The virus 
is not very stable in the environment and is inactivated easily by heat and by 
common disinfectants (Murphy et al., 1999). 
2-7 Viral Replications: 
Because of the lack of reliable cell culture system, the events of HCV 
RNA replication are only poorly understood. Detection of viral plus and 
minus-strand RNAs in infectious culture system or clinical samples has been 
limited to RT-PCR amplification (Mita., et al., 1994). Researchers proposed 
that HCV particles bind with a receptor on the surface of a cell membrane, 
then the virion somehow fuses with the cell membrane and enter inside the 
cell cytoplasm (Forns & Buch, 1999). 
      Viral RNA is translated into long protein sequences, which are then 
cleavage by cellular and viral proteins into smaller components. The same 
RNAs are also copied into complementary RNAs that serve as templates for 
making many progeny RNAs. After assembly of virion particles these are 
secreted from the liver via the cell’s secretary pathway, releasing the new 
virions to infect a large number of new liver cells (Choo et al., 1994). 
2-8 Viral Proteins: 
The organization and processing of the HCV polyprotein is show in figure (3). 
Ten major polypeptides are produced by co-or posttranslational cleavage of 
polyprotein into 10 viral protein named, core protein, E1, E2, P7, NS2, NS3, 
4A, NS4B, NS5A and NS5B. (Knipe et al., 2001).  
2-9 Epidemiology: 
Hepatitis C is a disease with a world wide distribution, although the 
prevalence varies broadly among geographic areas. It is estimated that there 
are 170 million chronic carriers of HCV in the world (Crowe et al., 1995). 
HCV infection occurs among persons of all ages (Table 3), but the highest 
incidence of acute hepatitis C is found among persons aged 30-40 years, and 
among males (McQuillan et al., 1997). Because most infections with HCV 
become persistent, spread is primarily by parenteral exposure to the blood of 
chronically infected individuals. Therefore, factors such as social and cultural 
customs for instant tattooing, improper medical practices, dialysis machine, 
and individual behaviors that lead to exchange of blood between individuals 
can all contribute to the infection rates in specific area or a country (Knipe et 
al., 2001). 
 
 
  
 
 
 
 
  
 
      Figure (2):  Genetic organization of the HCV genome (Web Site1) 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
       Figure (3) organization and processing of the HCV polyprotein (Web 
Site1) 
 
 
 
 
 
2-10 Mode of Transmission: 
        HCV is transmitted, to some degree, in similar way as HBV. The primary 
mode of transmission is via exposure to infected human unscreened blood and 
intravenous drug use.  
      Nosocomial HCV transmission during dialysis, colonoscopy, and surgery 
has also been reported (Laure and Walker., 2001). Vertical or sexual 
transmission is less common.  
2-10-1 Transfusion: 
Infected blood and blood products are the most common factor for 
HCV transmission (Alter et al., 1990). Recipe of clotting factor prepared from 
plasma pools poses a higher risk for HCV infection unless an effective 
procedure to inactivate the virus is introduced. 
2-10-2 Transplantation:  
Organ transplantation (e.g. heart, kidney or liver) from infectious 
donors to healthy recipient also predisposes a high risk for transmitting HCV 
infection (Pereira et al., 1992). 
2-10-3 Injection and other Illegal Drug Use: 
Although the number of cases of acute hepatitis C among injecting-drug 
users has declined dramatically since 1989 both incidence and prevalence of 
HCV infection remain high in this group (Villano 1997, and 
Everhart et al., 1990). Transmission is common by sharing syringes and 
needles among drug users (Koester 1994 and Heimer et al., 1996). 
2-10-4 Sexual Transmission: 
Sexual transmission of HCV is not as common as it is with HBV, but it 
seems to occur (Brettler et al., 1992). Transmission by male homosexual 
practices occurs less frequently than that of HBV (Bodsworth et al., 1996, and 
Osella et al., 1998). 
2-10-5 Nosocomial and Occupational Exposures: 
Nosocomial HCV transmission during dialysis, colonoscopy and 
surgery is possible if infection-control technique or disinfection procedures 
are inadequate (Laure and Walker., 2001). 
2-10-6 Vertical Transmission: 
This occurs during pregnancy, at birth or by breast feeding. However, 
many HCV positive women have given birth to HCV negative babies. Breast 
milk transmits the virus to less extend compared to condition in which the 
mother has cracked nipples and the baby has mouth ulcers (Ohto et al., 1994). 
 
 
 
 
Table (3): Epidemiologic and clinical feature of viral hepatitis type A, B 
and C (Albert  et al., 1991). 
 Viral Hepatitis Type A Viral Hepatitis Type B Viral Hepatitis Type C  
Incubation period 10-50 days (avg, 25-30) 50-180 days (avg, 60-
90) 
40-120 days. 
Principal age distribution Children, young adults. 15-29 years Adults. 
Seasonal incidence Throughout the year but 
tends to peak in autumn. 
Throughout the year 
 
Throughout the year. 
Route of infection Predominantly fecal-oral. Predominantly 
parenteral 
Predominantly 
parenteral 
Occurrence of virus 
blood 
2 weeks before to < 1 week 
after jaundice  
Months to years Months to years 
Stool 2 weeks before to 2 weeks 
after jaundice  
Absent Probably absent 
Urine  Rare Absent Probably absent 
Saliva, semen  Rare, (saliva) Frequently present Unknown 
Clinical and laboratory 
features Onset 
Abrupt. Insidious. Insidious  
Fever > 38oC (100.4oF) Common Less common Less common 
Duration of aminotrans-
ferase elevation 
1-3 weeks 1-6+ months 1-6+ months 
Immunogiobulins (1gM 
levels) 
Elevated Normal to slightly 
elevated 
Normal to slightly 
elevated 
Complications Uncommon, no chronicity  Chronicity in 5-10% Chronicity in 50% or 
more 
Mortality rate (icteric 
cases) 
<0.5% <1-2% 0.5-1% 
HbsAg Absent Present Absent 
Immunity Homologous Yes Yes ? 
Heterologous No No No 
Duration  Probably lifetime Probably lifetime ? 
Gammaglobulin 
(immunoglobulin USP) 
prophylaxis 
Regularly prevents jaundice Prevents jaundice only 
if gamma globulin is of 
sufficient potency 
against HBV 
? 
 
2-10-7 Body fluids: 
Body fluids as tears, saliva, urine and semen are poor means of 
transmission, even from chronic HCV patients (Fried et al., 1992). Body 
fluids from patients with chronic HCV were analyzed for the presence of 
hepatitis C viral RNA using the genomic amplification method (Reverse 
transcription followed by polymerase chain reaction (RT. PCR). The HCV 
genome was not detected (Fried et al., 1992). This may explain the infrequent 
transmission of this disease by sexual or close physical contact.  
2-11 Clinical Findings: 
The clinical features of infection by HAV, HBV and HCV are 
summarized in table (3). In individual cases, it is not possible to make a 
reliable clinical distinction among cases caused by the hepatitis viruses. 
Hepatitis may occasionally occur as a complication of leptospirosis, tuber- 
culosis, toxoplasmosis and ameobiasis. Non infectious cases include biliary 
obstruction, drug toxicity and drug hypersensitivity reactions. 
In viral hepatitis, the onset of jaundice is often preceded by 
gastrointestinal symptoms such as nausea, vomiting, anorexia, and mild fever. 
Jaundice may appear within a few days of the prodromal period, but an icteric 
hepatitis is more common.   
Complication associated with the chronic infection is liver cirrhosis 
which characterized pathologically by loss of the normal microscopic 
architecture of the liver with fibrosis and nodular regeneration. There are also 
increased risks of hepatocellular careinoma (Simonetti et al., 1992). 
2-12 HCV Clinical feature: 
2-12-1 Acute Infection: 
Persons with HCV infection typically are either a symptomatic or have 
a mild clinical illness or might have non specific symptoms such as malaise, 
anorexia, abdominal pain (Aach et al., 1991; Alter, 1992 and Alter, 1995).The 
clinical picture of acute hepatitis C resembles other forms of acute viral 
hepatitis. Biochemical evidence of hepatitis such as elevated levels of serum 
ALT, are observed in more than 80% of cases. Hepatitis C RNA can be 
detected in the serum early after exposure, usually within the first three weeks 
(Farci et al., 1991). The bulk of acute cases become chronic with active viral 
replication and persistence, despite a cellular and humoral immune response 
(Alter, et al., 1992).  Liver biopsy is not recommended for the diagnosis of 
acute viral hepatitis, and serological tests are necessary to determine the 
etiology of hepatitis in individual patients (Dienes et al., 1982). 
 
 
2-12-2 Chronic Infection: 
The single most important feature of HCV infection is the propensity of 
the virus to cause persistent infection. Chronically infected patient are the 
source of almost all new infections and themselves are at increased risk for the 
development of significant chronic liver disease, cirrhosis and hepatocellular 
carcinoma (Knipe et al., 2001). Almost all chronically infected individuals 
have histological evidence of ongoing liver disease. From biopsy samples 
about 10-20% of patients have the histological features of cirrhosis (Koretz et 
al., 1993). 
Many chronically infected patients do not have symptoms and can not 
be detected unless tested by their physicians or when they donate blood, other 
may develop severe chronic liver disease (Knipe et al., 2001). Chronic HCV 
infection can lead to end-stage liver cancer (Floreani, 1996). 
2-12-3 Hepatocellular Carcinoma (HCC): 
The most serious late outcome of chronic HCV infection is HCC. Most 
HCC cases are related to either chronic HBV or HCV infection. 
  Worldwide chronic infection with either virus results in chronic 
inflammation, necrosis, regeneration and cirrhosis, which are all related to 
increased risk for oncogenesis. Cirrhosis of almost any cause carries an 
increased risk for HCC (Schafer and Sorrell., 1999). 
2-13 Immune Responses: 
2-13-1 Humoral Immune Response: 
HCV-specific antibodies are generally detectable 7 to 31 weeks after 
infection (Chien et al., 1992). The humoral immune response is usually 
multispecific and targeted against epitopes within the HCV core, envelope, 
NS3, and NS4 proteins (Akatsuka et al., 1993; Ishida et al., 1993 and 
Simmonds et al., 1993). 
A major problem in assessing the relevance of these antibody responses is the 
lack of a convenient neutralization assay for HCV. As in other viral infection, 
antibody binding could interfere with HCV entry into host cells or viral 
replication, and it could opsonize virions for elimination by macrophages. 
However evidence for a protective role of antibodies stems from limited 
studies in which chimpanzee or tissue culture infectious HCV was neutralized 
in vitro by incubation with antibody. Thus far, the HCV E2 protein has been 
identified as the major target for neutralizing antibodies (Farci et al., 1996; 
Shimizu et al., 1996 and Yu MY et al., 1998). 
2-13-2 Cellular Immune Response: 
The cellular immune response is thought to play a particularly 
important role in the host’s defense against infections with virus is such as 
HCV, because of it is ability to recognize viral antigens and to eliminate the 
virus from infected cells. Although it is known that the liver is significantly 
enriched with cells of the innate immune response, the role of the innate and 
antigen non specific immune response to HCV has not been sufficiently 
studied (Knipe et al., 2001). 
2-14 Persistent Infection: 
Viral infections may generally be categorized as cytocidal or non 
cytocidal. Further, not all viral infections are productive, i-e not all infections 
lead to the production and release of new virions. Some of the most important 
of all non productive virus cell interactions are those associated with 
persistent infections or latent infections. The term persistent infection simply 
describes an infection that lasts along time. The term latent infection describes 
an infection that “exists but is not exhibited”. (Murphy et al., 1999). 
2-14-1 Mechanisms of Persistence: 
The Mechanisms whereby HCV circumventers the immune response, 
persists, and causes chronic inflammatory liver disease are currently 
undefined. One hypothesis is that the HCV-specific immune response is too 
weak to clear HCV from all infected hepatocytes once a persistent infection is 
established. This may be due either to an insufficient induction of the primary 
immune response during acute infection (Cooper et al., 1999) or to the 
inability to maintain the T-cell response at high levels during chronic hepatitis 
C (Gerlach et al., 1999). Generally, the intensity of the initial immune 
response depends on antigenic load, co-stimulatory signals, the type of the 
antigen-presenting cell, and differentiation and cytokine profile of helper T 
cell. Each of these factors may not be optimal in acute HCV infection 
because, for example, the display of HCV antigens is relatively low and co-
stimulatory molecules are dominantly expressed on professional antigen-
presenting cells in the lymph nodes and not on hepatocytes, the preferred cell 
type for HCV replication. Second recent reports indicate that individual HCV 
proteins may actively suppress the immune response of the host. A third 
hypothetical explanation for HCV persistence could be the high genetic 
variability of the virus due to a lack of proof reading activity of the viral RNA 
polymerase (Choo et al., 1989). 
2-15 Diagnosis of HCV Infection: 
The common tests used for diagnosis of HCV infection were designed 
primarily for screening of blood donors. These assays are based on detection 
of serum antibody to various HCV antigens. The serological tests often fail to 
detect antibody in window period between the time of infection and the time 
of appearance of detectable antibody. Tests for HCV RNA genome detection 
based on the PCR or other highly sensitive RNA detection systems have been 
used for the diagnosis of acute hepatitis (Knipe et al., 2001). Different 
laboratory assays for the diagnosis and management of HCV infection were 
reported. 
2-15-1 Serological Tests: 
2-15-1-1 Enzyme Immune Assay (EIA): 
      The initial test used to diagnosis HCV is an enzyme immuno assay 
(EIA) for anti-HCV immunoglobulin G (IgG). The hepatitis C virus 
genome encodes a polyprotein of 3.001 to 3.033 amino acid that is 
processed into 10 structural and non structural (NS) proteins (Bendinelli et 
al., 2000). Three generations screening EIAs have been developed to 
detect antibodies against various epitopes of these proteins (Figure 3). First 
generation EIAs used the 100-3 epitopes of a non structural protein (NS4) 
(Kuo et al., 1989). Second-generation (EIAs 2.0) that incorporated 
additional antigens from NS (C33C) and structural (C22-3) proteins, that  
is approved for use by the Food and Drug Administration (FDA) (Alter, 
1999). In 1996, FDA approved a third-generation EIA (EIA 3.0) that added 
a fourth antigen (NS5) (Barrera et al., 1995). 
2-15-1-2 Recombinant Immuno Blot Assay (RIBA): 
(RIBA) is a form of western Blot Assay for the detection of HCV-Abs. 
It is a technique in which recombinant HCV Ag is electophoresed in 
polyacrylamide gel, transferred on to nitrocellulose and incubated with patient 
seum. HCV-Abs is then detected by using anti-human IgG antibody 
conjugated with an enzyme which will produce colored bands upon addition 
of a substrate. Molecular weight standard, positive and negative control sera 
run simultaneously to allow the identification of the viral bands, which are 
usually read by the naked eye. This assay has the advantage of identifying 
antibodies specific for HCV antigens (Pawlotsky et al., 1996). 
2-15-1-3 Immunochromatography Technique (ICT): 
The HCV (ICT) or one step test device (serum / plasma) is a rapid 
immunoassay for the qualitative detection for the presence of antibodies to 
HCV (Choo et al., 1989). ICT is modeled after the home pregnancy tests used 
by women in many countries. it differ from usual systems for measuring 
antigen-antibody reactions in that the specimen from the human subject is 
made to flow through a filter after which it is immobilized in a membrane at a 
site where antigen (or antibody) in the specimen comes into contact with the 
test antibody (or antigen) already present in the membrane. All controls are 
included in the membrane as well, and results are seen as colored bands or 
lines, as one of the test reagents is conjugated to colloidal gold or 
chromogenic substance (Murphy et al., 1999). 
 
 
2-15-2 Nucleic Acid Test: 
2-15-2-1 HCV RNA Detection and Quantification: 
      The presence of HCV RNA in plasma defines active infection, and 
HCV RNA can be detected 1 to 3 weeks post exposure. A single negative 
HCV RNA assay result does not exclude the possibility of active infection 
with the transient drop in the level of viremia below the assay’s limit of 
detection. (NIH. 1997). 
2-15-2-2 Reverse Transcriptase-polymerase Chain Reaction (RT-PCR): 
The polymerase chain reaction (PCR) is an in vitro method for 
enzymatic synthesis of specific DNA sequence using two oligonucleotide 
primers (Bukh et al., 1993). Because of the limited amount of HCV RNA in 
infected individuals, a target or a single amplification step is needed (Tang et 
al., 1999). 
The development of (RT-PCR) method to assist in detection of RNA 
viruses has been a major advance in viral diagnostic and research. The RNA 
template like HCV is first transcribed into cDNA using RT derived from 
thermophilic bacteria (Bukh et al., 1993). 
PCR is useful in the diagnosis of virus infection when viral antigenes or 
virus specific antibodies can not be detected and when the presence of viral 
nucleic acid may be the only evidence of infection. This particularly true for 
latent virus infections, non cultivable viruses, like HCV, or those difficult to 
cultivate and for virus is that grow without a visible cytopathic effect (figure 
4). For zoonotic viruses PCR is preferred to minimize the risk of exposure for 
laboratory personal (Bell et al., 1997). 
2-15-3 other laboratory and Clinical Tests: 
The diagnosis of liver disease depends upon a combination of history, 
physical examination, laboratory testing and sometime, radiological studies 
and biopsy.  
2-15-4 Ultrasound Scan of Liver: 
Is a routine test which does not show how much damage there is to the 
liver but it gives an indication of the shape and size of the liver (Mawat et al., 
2001). 
2-15-5 Liver Function Tests: 
These are routine tests performed in the investigation of a liver disease, 
these tests are non-specific and in most cases are not true indications of liver 
dysfunction. They are only suggestive liver disease (Mowat et al., 2001). 
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Figure (4): HCV-infection-testing for diagnosis of asymptomatic person. 
(Web site 1). 
      The enzymes, AST previously known as glutamate oxaloacetate 
transaminase (GOT), is concerned with amino acid metabolism. Large 
amounts of (AST) are present in the liver, kidneys, cardiac muscle. Small 
amount of the enzyme are present in the brain, pancreas, and lungs. In district 
laboratories the measurement of (AST) activity is mainly performed to 
investigate liver disease and myocardial infarction (Cheesbrough., 1998). 
2-15-5-2 Alanine aminotransferase (ALT): 
The enzyme, ALT formerly known as glutamate pyruvate transaminase 
(GPT), is concerned with alanine metabolism. ALT is found principally in the 
liver with only small amounts being present in other organs (figure 5). When 
there is liver cell damage the serum or plasma levels of enzymes are raised 
(Cheesbrough, 1998). 
2-15-5-3 Albumin: 
Albumin is produced entirely in the liver and constitutes about 60% of 
total serum protein. It is important in regulating the flow of water between the 
plasma and tissue fluid. When the concentration of albumin is significantly 
reduced, the plasma osmotic pressure is insufficient to draw  
 
  
Figure (5): Different methods used in diagnosis of HCV (Kumar and 
Clark 2004)  
 
 
 
 
water from the tissue spaces back into the plasma. This leads to a build-up of 
fluid in the tissues, culminating in oedema. Albumin also has important 
binding and transport function. It binds and inactivates substances including 
calcium, fatty acid, hormones, and magnesium. When albumin levels are 
reduced, toxic effects can develop from an increase in unbound substances. 
(Cheesbrough, 1998). Low serum albumin concentration indicates poor liver 
function. 
2-15-5-4 Bilirubin: 
Bilirubin is formed from the break down of erythrocytes and other 
haem-containing proteins such as myoglobin and cytochromes. It is of two 
types, unconjugated (indirect) bilirubin which is not soluble in water and can 
not be excreted in the urine. It is bound to albumin and transported in the 
blood to the liver. This bilirubin is referred to as conjugated (direct) bilirubin 
and is water-soluble (Cheebrough., 1998). If the liver is not functioning well 
there is a decreased removal of the bilirubin from the blood stream (Mowat et 
al., 2001). 
2-15-5-5 Prothrombin Time (PT): 
Many factors necessary for blood clotting are made in liver. When liver 
function is severely abnormal, their synthesis and secretion into the blood is 
decreased. The PT is a type of blood clotting test performed in the laboratory 
and it is prolonged when the blood concentration of some of the clotting 
factors made by the liver are low. The PT can also be prolonged in case of 
vitamine K deficiency and by drugs. 
2-15-5-6 Alkaline Phosphatase (AP): 
Alkaline phosphatase is an enzyme, or more precisely a family of 
related enzymes, produced in bile ducts, intestine, kidney, placenta and bone. 
An elevation in level of serum AP suggests disease of the bile duct. 
 2-15-5-7 Gamma-glutamyltranspeptidase (GGT): 
GGT an enzyme produced in bile ducts that, may be elevated in the 
serum of patient with bile ducts disease. Measurement of GGT is an extremely 
sensitive test, however, and it may be elevated in virtually any liver disease. 
2-16 Genotyping: 
On the bases of its extensive genetic heterogenecity. HCV has been 
divided into six major genotypes (represented by Arabic numerals) and at 
least 80 subtypes (represented by lower case letter) (Davis, 1989). Genotype 
1, 2 and 3 found throughout the world; but the other genotypes are common in 
particular geographic regions, genotype 4 is common in North Africa, and 
genotype (5) is common in South Africa, and genotype (6) is common in 
South East Asia (Zein ., 2000). 
2-17 Treatment: 
Interferon Alpha was the only treatment licensed for use in hepatitis C 
infection. With this treatment the cure rate was about 10-15% of patients, 
having a long-term response (Davis., 1989 and Di Bisceglie, 1989). Recently 
Ribavirin has been licensed for use in combination with interferon Alpha, 
which is now the “gold standard” treatment for HCV infection (Davis., 1989 
and Pol et al., 1999). 
Ribavirin is given as tablet to be taken each day either for 6 month or 
one year depending on the genotype. Interferon Alpha involves injection 
under the skin three times a week (Krajden, 1995). 
2-18 Prevalence of HCV: 
      Hepatitis C virus is a global disease. While not every nation in the world 
has had adequate means to survey its population for incidence of the virus, 
enough statistic have been complied to demonstrate the enormous threat posed 
by hepatitis C. In combination with hepatitis B it accounts for 75% of all cases 
of liver disease around the world. The global prevalence of HCV carriers is 
estimated to average 3%, ranging from 0.1 to 10% or more in different 
countries (Cohen 1999). In Europe, the overall prevalence is 1% with a north 
– south gradient, ranging from 0.5% in northern countries to 2% in 
Mediterranean countries. 
             Recent studies have shown high prevalence in Eastern Europe, 
ranging from 0.7% to 5 %. In Asia, Mongolia, Vietnam, Myanmar and China 
show high prevalence. In Africa, high prevalence is seen in central region 
countries and Egypt (Frank et al., 2000) In North America, high prevalence is 
relatively low. In South America, high prevalance is seen in Brazil 
(Schumuniz etal, 1998). The highest prevalance (10% or more) is seen in 
Mongolia, Tanzania, Guinea and Cameroon (Cohen etal, 1999). There are 
reasons for the high prevalance of HCV carries in each of these regions. For 
example, in Egypt the use of parenteral antischistosomal therapy is thought to 
have contributed to the prevalence of HCV (Frank et al ., 2000). 
Among newly detected HCV cases, 40-60% have normal alanine 
aminotransferase (ALT) levels, 80% are viraemic, while about 70% of newly 
detected HCV carriers present histological liver disease as (Trepo and Pradat 
1999). 
2-18-1 Prevalence of HCV in the Sudan: 
      Few HCV seroprevalence studies were conducted in the Sudan. In a study 
done in Juba in Southern Sudan to compare the epidemiology of HBV with 
HCV among 666 out – patient attending 6 public clinics in the city. HBs Ag 
was found in 26% and – HBc Ag in 76% In contrast only 3% of the 
populations were HCV Abs positive. This study indicated that HCV Infection 
is not highly endemic in this population. (Mc Carthey et al., 1994). 
 In another study on acute viral hepatitis in Khartoum, antibodies to 
HCV were detected in 13% of the patients examined while antibodies to HBV 
marker were detected in 82% of the patients (Dimitry 1996). The prevalence 
of HCV infection was also studied in patients under going haemodialysis in 
Sudan and 34.9% of the patients were confirmed positive for HCV. It was 
conclude that prevalence of HCV antibodies was high in the haemodialysis 
population in the country (Suliman et al , 1995).  
 Other studies done in Sudan were conducted to conclude the prevalence 
of HBs – antigens and HCV –antibodies in patients with hepotocellular 
carcinoma which gave a prevalence of 38.7% and 17.3% respectively (Salma 
1998). Another Study was done in patient with liver Cirrhosis and the 
prevalence was found to be 18% for both HBs and HCV (Abdel Rahman 
2000).  
 Incidence of hepatocellular carcinoma is high and increasing in Sudan. 
Therefore Omer et al (2001) carried- out a study to elucidate the role of 
hepatitis B and hepatitis C viral infection in the incidence of HCC. A case – 
control study was conducted in 1996 – 1998 among 150 HCC patients and 
205 controls from two regions in the Sudan (Omer et al., 2001). one hundred 
and fifteen cases and 199 controls were tested for HBs and for HCV – Abs. 
Strong positive association were found between  HBV or HCV and HCC , 
giving a prevalence of HBV and HCV of 7.0% and 1.5% among controls. 
About 57% of all HCC cases were attributed to these viral infections. 
Hepatitis infection seem to be an important factors for HCC in Sudan (Omer 
et al., 2001)  
2-19 Prevention and Control: 
Reducing the burden of HCV infection and HCV-related disease in the 
United States requires implementation of primary and secondary prevention 
activities that reduce the risk for contracting HCV infection. 
2-19-1 Primary prevention: 
            Screening and testing of blood, plasma, organ, tissue and semen 
donors. Also by virus inactivation of plasma-derived products. Risk-reduction 
counseling and services. Implementation and maintenance of infection-control 
practices. 
2-19-2 Secondary prevention: 
         Secondary prevention includes medical management of infected 
person’s by identification, counseling and testing of persons as well as by 
Professional and public education. Surveillance and research to monitor 
disease trends and the effectiveness of prevention activities and to develop 
improved prevention methods. 
       There is no vaccine against HCV, therefore control measures, largely 
depends on avoiding the risk factors. In blood banking, all blood donors 
should be screened for HCV-Abs before blood transfusion.  
2-19-3 Passive Immunization: 
Some recent studies indicate that the passive immunoprophylaxis of 
HCV infections may be possible. Pooled immunoglobulin with a high titer of 
anti-HCV was mixed with HCV in vitro, and this mixture was shown to be 
noninfectious when injected into a chimpanzee (Yu MY,  et al., 1998). The 
place for passive immunization with high tittered immunoglobulin 
preparations in the prevention of HCV infection in humans has not been 
determined. 
2-19-4 Active Immunization: 
HCV itself presents numerous problems that complicate the 
development of an effective vaccine. The lack of a suitable in vitro culture 
system makes production of adequate vaccine quantities of whole virus 
impractical. The genomic diversity of the virus and the high level of mutation 
also complicate vaccine development. A vaccine based on the E1 and E2 
glycoproteins was tested in chimpanzees (Choo et al., 1994). The vaccine 
produced an antibody response to E1 and E2 but it was short lived and 
required frequent boosting (Maini et al., 1991). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Three 
Materials and Methods 
3-1 Collection of samples: 
A total of 380 blood samples were collected from different groups at the 
area of study, Khartoum State. These groups include: 
1- Blood donors group: 295 blood samples were collected from blood 
donors. 
2- Multiple transfused individuals: 20 blood samples were collected from 
multiple transfused individuals. 
3- Haemodialysis patients group: 65 blood samples were collected from 
haemodialysis patients. 
Blood was collected from the vein using vacutainers containing heparin, 
and centrifuged to separate the plasma which was used for the detection of 
HCV-antibodies. The plasma was stored at temperature between 2-8oC for no 
longer than 72 hours after collection. For longer periods, the samples were 
kept at (-20oC). And multiple freeze-thaws were avoided. 
3-2 Immunochromatogrophy technique for the detection of HCV-
antibodies: 
3-2-1 Materials provided:  
(a) Test devices. 
(b) Disposable specimen droppers. 
(c) Buffer. 
3-2-2 Materials required but not provided: 
(a) Specimen collection containers. 
(b) Pipette and disposable tips. 
(c) Centrifuge. 
(d) Stop watch 
3-2-3 Storage and stability: 
The kits were stored at room temperature or refrigerated (4oC). The test 
devices were kept in the sealed pouch until use. The expiry date was observed.   
3-2-4 Test procedure: 
      Specimens were allowed to reach room temperature (20-25oC) before 
running the test. Frozen specimens were completely thawed and mixed well 
prior to testing. Freezing and thawing was avoided. Then the test device and 
buffer were allowed to equilibrate at the room temperature.  Test device were 
removed from the foil pouch and used immediately and the test is performed 
within one hour. Five µL of plasma were transferred into the specimen well, 
and then two drops of buffer (approximately 80 µL) were added carefully to 
avoid trapping air bubbles in the specimen well. Results were read after 10 
minutes as indicated by the appearance of red line of the control (figure 6). 
 3-2-5 Interpretation of results: 
(a) Positive test: Two distinct red lines appear, one line should be in the 
control region (C) and the second one in the test region (T). 
(b) Negative test: When one line appeared in the control region (C). 
(c) Invalid test: If no line appeared on the positive control region. 
3-3 Indirect ELISA for the Detection of HCV-antibodies: 
3-3-1 ELISA kits: 
The ELISA kits were purchased from Biokit, A.S. Spain and supplied as 
follows: 
1- Microtiter plate 12 x 8 wells coated with HCV recombinant antigens. 
2- Concentrated conjugate. Rabbit anti-human IgG antibodies conjugated 
with peroxidase. Contains red dye, preservatives and protein stabilizers. To 
be diluted   1/51 with the conjugate diluents just before use. 
3- Conjugate diluents. Tris buffer containing yellow dye, additives and 
preservatives. 
4- Sample diluents. Tris buffer with protein stabilizers and sodium azides 
as preservation. 
 
 
 
  
Figure (6): Principle of ICT method 
 
 
 
 
 
 
5- Concentrated washing solution is phosphate buffer containing 1% 
tween 20 and 0.01% thimerosal 
6- Substrate solution which is citrate-acetate buffer containing hydrogen 
peroxide. 
7- Chromogen which is 3, 31, 5, 51- tetramethyl benzidine (TMB) 
dissolved in dimethyl sulphoxide (DMSO).  
8- Positive control which is diluted heat inactivated human serum 
containing antibodies to HCV. It contains sodium azide as preservative and 
green dye. 
9- Negative control which is diluted human serum negative for anti-HCV. 
Contains sodium azide as preservative and yellow dye. 
10- Stopping solution which is 1N sulphuric acid. 
11- Adhesive seals to cover plate during incubation. 
12- Resealable bag for storage of unused strips of micro-titer plate 
3-3-2 Other materials not included in the kit: 
1- Distilled or deionized water. 
2- Multichannel pipette and micropipettes. 
3- Automated wash system. 
4- Microplate reader with 450 nm filter. 
5- Incubator with high relative humidity, at 37oC. 
3-4 Storage of ELISA kits: 
All kits components were stored at 2-8oC. The bag containing the 
microtiter plate should be brought to room temperature before opening to 
avoid condensation in the wells. Unused strips of micro-titer plate should be 
stored between 2-8oC tightly sealed in the plastic bag provided with the silica 
gel bag inside. The washing solution once diluted is stored between 2-8oC. 
The diluted conjugate is stable for 15 days at 2-8oC. The chromogen was 
stored protected from light whereas substrate –TMB solution was prepared 
according to the manufacture instructions.  
3-5 Test procedure: 
3-5-1 Preparation of reagents: 
 Reagents were allowed to reach room temperature (20-25oC) before 
running the assay. All liquid reagents were mixed before use. The 
concentrated washing solution is diluted (1/10) with distilled water. The 
concentrated conjugate is diluted (1/51) with the conjugate diluents. All 
dilutions were made according to the manufacture instructions. 
3-5-2 Assay procedure:   
Six wells were reserved for one blank, three negative controls and two 
positive controls, each filled with 200µL of the appropriate serum control. 
Two hundred µL of sample diluents and 10 µL of each sample were 
distributed to the designated wells. The plates were covered with the adhesive 
seals, mixed gently and incubated for 1 hour at 37oC. There after the adhesive 
plate covers were removed and the content was discarded by aspiration and 
each well was filled approximately with 300 µL diluted washing solution. 
This process was repeated five times. After the last washing the microplates 
were blotted on absorbent tissue to remove any excess liquid from the wells. 
Then 100 µL of diluted conjugate were transferred into each well of the 
microplates, except the blank. The plates were covered again with the 
adhesive seals and incubated for 30 minutes at 37oC.  
The adhesive plate covers were removed and discarded. The plate’s 
contents were aspirated and washed six times with washing buffer. Then 
100µL of substrate-TMB solution were added to each well. All plates were 
incubated uncovered for 30 minutes at room temperature. The reaction was 
stopped by adding 100µL of stopping solution in the same sequence and time 
intervals as for the substrate-TMB addition. The spectrophotometer was 
blanked at 450nm with the blank well and the absorbencies of each well were 
read within 30 minutes. 
3-5-3 Reading of the test: 
For the validity of the assay the accomplishment of the following points 
were observed: 
a- Negative control means (NCx): Absorbance of individual negative 
control values must be less than or equal to 0.200 OD. 
b- Positive control mean (PCx): It must be equal or greater than 0.800 OD. 
c- The presence or absence of anti-HCV antibodies in the samples 
analyzed was determined by relating the absorbance value of each sample 
to the cut-off value of the technique. This value was the mean value 
obtained from the negative control plus 0.300 OD. 
Cut-off = NC + 0.300 OD. 
3-6 Interpretation of the test: 
If the test value of a sample was above the calculated cut-off value, the 
test serum was considered positive and if the test value was lower than the 
cut-off value, the sample was considered negative for the presence of HCV-
antibodies. However, sera having test values equal to the cut-off value, these 
sera should be retested in duplicates and if one duplicate has a value above the 
cut-off value the test was considered positive even if the other duplicate value 
was below the cut-off value. 
3-7 Estimation of liver enzymes: 
      The fallowing equipment and reagents were required for estimation of 
liver enzymes.  
3-7-1 Materials  
1. Digital spectrophotometer (Haemolyzer 2000) 
2. GOT, GPT and ALP reagents. 
3. Precision micropipettes. 
4.  100µL and 200µL tips for Precision micropipettes. 
5. Test tubes.                 
3-7-2 Reagent stability and storage  
          All reagents were stored at 2-8 oC and closed immediately after use to 
avoid contamination .The reagents  were kept stable for four weeks at 2 -8 oC 
and for five days at room temperature, protected from light . 
3-7-3 Test procedure 
3-7-3-1 Alkaline phosphatase (ALP)  
            Specimens and reagents were allowed to reach room temperature. 
Then one ml of Butter (Diethanolamin pH 9.8, Magnesium chloride) was 
transferred into the test tube, and 200µL of sample was added, mixed and 
incubate for approximately one minute.  Then 250µL of the substrate was 
added (p – nitrophenylphosphate), mixed and the optical densities were read at 
three intervals at one minute each.  
* Test principle  
Under alkaline condition, colorless P – nitrophenylphosphate was converted to 
4- nitrophenoxide, which developed a very intense yellow color. Its intensity 
was proportional to the activity of alkaline phosphates in the sample. 
P – Nitrophenylphosphate +H2O +APL, pH 9.8               4- nitrophenoxide    
      Calculation:  ∆ A/min x factor =IU/L ALP in sample 
3-7-3- 2Glutamate Oxaloacetate Transaminase GOT (AST):                                 
specimens and reagents were allowed to reach room temperature. Then one ml 
of (Buffer) pH 7.8 was transferred into the test tube , then  200µL of  the 
sample were added , mixed and incubated for approximately one minute.  
Then 250µL of the substrate was added, mixed and the optical densities were 
read at three intervals at one minute each. 
      Calculation:  ∆ A/min x factor =IU/L GOT in sample   
3-7-3-3 Glutamate – Pyruvate Transaminase GPT (ALT)  
            Specimens and reagents were allowed to reach room temperature. 
Then one ml of (Buffer) pH 7.5 was transferred into the test tube , then  
200µL of sample was added, mixed and incubated for approximately five 
minutes , then 250µL of  the substrate were added , mixed and the optical 
densities were read at three intervals at one minute each.   
      Calculation:  ∆ A/min x factor =IU/L GPT in sample   
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter Four 
Results 
 
          The presence of anti- HCV antibodies and the estimation of the level of 
liver enzyme in sera of the different groups of patient were as follows: 
4-1   ICT Results: 
             295, 20 and 65 blood samples were collected from blood donors, 
multi-transfused and haemodialysis patients respectively. Two (0.67%), one 
(5%) and eight (12.3%) samples we found positive for HCV – antibodies 
respectively when screened by ICT (Table 4). 
4-2   ELISA Results: 
            In contrast to the previous test, the same samples when tested by 
ELISA using recombinant HCV- antigens three (1.0%), one (5%) and nine 
(13.8%) samples were positive for HCV – antibodies when blood donors, 
multitransfused and haemodialysis patients were tested respectively. (Table 
5). 
       Table (7) shows the optical density of each HCV positive sample. This 
optical density varied between each sample and was proportional to the total 
HCV – antibodies titer in each patient. 
 
 
4-3 Comparison between ICT and ELISA: 
       In comparison between ICT and ELISA, ELISA has detected two positive 
samples that were found negative by ICT test. However there was a very high 
concordance between ICT and ELISA and no statistical significant difference 
was obtained by the application of (T.TEST) and both assay were sensitive, 
specific and reliable (Table 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table (4):  Total HCV positive individual in various groups screened by 
(ICT). 
 
Total HCV% 
positive 
Number of 
HCV% positive 
in group 
Number of HCV 
positive in group 
Number 
screened 
Group tested 
 
0.52% 
 
0.67% 
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295 
Blood donors 
 
0.26% 
 
5% 
 
1 
 
20 
Multi- 
transfused 
 
2.1% 
 
12.3% 
 
8 
 
65 
Haemodialysis 
patients 
 
2.89% 
  
11 
 
380 
 
Total 
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Figure (7): Total HCV positive individual in various groups screened by 
(ICT) 
 
 
1= Blood donors 
2= Multiple transfused 
3= Haemodialysis patients 
 
 
 
 
 
 
 
 
 
Table (5): Total HCV positive individual in various groups screened by 
(ELISA). 
 
Total HCV% 
positive 
Number of 
HCV% positive 
in group 
Number of HCV 
positive in group 
Number 
screened 
Group tested 
 
0.78% 
 
1.0% 
 
3 
 
295 
Blood donors 
 
0.26% 
 
5% 
 
1 
 
20 
Multi- 
transfused 
 
2.3% 
 
13.8% 
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65 
Haemodialysis 
patients 
 
3.4% 
  
13 
 
380 
 
Total 
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Figure (8): Total HCV positive individual in various groups screened by 
(ELISA). 
 
 
1= Blood donors 
2= Multiple transfused 
3= Haemodialysis patients 
 
 
 
 
 
 
 
  
Table (6): Statistical comparison between ICT and ELISA results. 
  
 Results 
ICT 11 
ELISA 13 
STANDARD ERROR 
MEAN 
0.1 
T. VALUE 1.477 
SIGNIFICANT (2 – 
TAILED) 
0.165 
LEVEL OF 
SIGNIFICANCE 
NOT SIGNIFICANT 
DIFFERENCE 
 
* Both tests are sensitive and specific.   
 
 
 
 
 
 
 
 
 
  
 
Figure (9): Statistical comparison between ICT and ELISA results 
 
 
1= Blood donors 
2= Multiple transfused 
3= Haemodialysis patients 
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 4-5 Estimation of liver enzymes:  
           Thirteen (3.4%) of 380 serum samples with HCV – antibodies  were 
investigated to determine ALT, AST and ALP levels. Normal ALT level were 
found to be ≤ 31U/L, AST ≤ 40U/L and ALP ≤ 53-128 U/L , when tested at 
37oC shown in (table 8). 
           Samples obtained from blood donors and multitransfused individuals 
showed normal ALT, AST and ALP, but samples obtained from 
haemodialysis patients showed elevated ALT (>31U/L), AST (>40U/L), and 
ALP (>53-138 U/L) titers. (Table 8) 
 4-6 Risk factors associated with HCV positive samples: 
Table (9) and (10) summarizes the data obtained from questionnaire and all 
risk factors that might contribute to HCV infection. All patients who were 
positive for HCV – antibodies have an age ranging between 25-52 years, we 
found all haemodialysis patients have received blood transfusion, and HCV 
infection in this group is probably blood transfusion mediated disease. Sex 
and tattooing have no role in predisposition to the disease. In the group 
studied high incidence of HCV antibodies (12.3%) was found in 
haemodialysis group and probably haemodialysis machine have a role in 
transmission of the disease. 
  
Table (7): Optical density of each HCV positive samples 
 
Optical density Number of 
samples 
0.97 1 
1.01 2 
1.04 3 
1.13 4 
0.89 5 
0.93 6 
1.74 7 
1.05 8 
1.75 9 
0.84 10 
1.59 11 
1.00 12 
1.83 13 
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 Figure (10): Optical density of each HCV positive samples 
 
 
 
 
 
 
 
 
 
  
 
Table (8): The level of liver enzymes in patients with positive HCV – 
antibodies. 
 
TESEED 
GROUPS 
ALP .NV= 
53-128 U/L 
AST(GOT) 
NV=40U/L 
ALT(GPT) 
NV=31U/L 
Number of 
samples 
Haemodialysis 183 147 120 1 
Haemodialysis 216 120 168 2 
Haemodialysis 145 185 175 3 
Haemodialysis 138 53 46 4 
Haemodialysis 171 145 195 5 
Haemodialysis 220 180 130 6 
Haemodialysis 163 130 110 7 
Haemodialysis 182 189 85 8 
Haemodialysis 185 175 92 9 
Blood donors 122 27 35 10 
Blood donors 112 30 22 11 
Blood donors 125 30 37 12 
Multitranfused 120 32 39 13 
 
*NV = Normal value at 37oC.  
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Figure (11): The level of liver enzymes in patients with positive 
HCV-antibodies.  
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Table (9): Risk factor associated with HCV positive samples in 
each group. 
HM SC AD IVDU
illegal 
tattooing Operations Blood 
donate 
Previous 
blood 
transfused 
NO of 
sample 
+ — — — — + — + 1 
+ — + — — — + + 2 
+ — — — — — — + 3 
+ — — — — + — + 4 
+ — — — — — + + 5 
+ — + — — — — + 6 
+ — — — — + — + 7 
+ — — — — — — + 8 
+ — + — — — — + 9 
— — — — — — + — 10 
— — — — — — + + 11 
— — — — — — + — 12 
— — — — — — — + 13 
 
IVDU = Intravenous Drug Users. 
AD = Alcoholic Drink  
SC = Sexual Contact 
HM = Haemodialysis Machine 
Table (10): Data obtained from the questionnaire. 
 
Liver enzyme 
ALP GPT GOT 
HM SC AD IVDU TA OP BD 
 
PBT Age Sex NO of 
samples 
 abnormal abnormalabnormal Yes NO NO NO NO Yes Yes Yes 38 M 1 
abnormal abnormalabnormal Yes NO NO NO NO NO NO Yes 52 F 2 
abnormal abnormalabnormal Yes NO Yes NO NO NO NO Yes 49 M 3 
abnormal abnormalabnormal Yes NO NO NO NO Yes NO Yes 28 M 4 
abnormal abnormalabnormal Yes NO NO NO NO NO Yes Yes 45 M 5 
abnormal abnormalabnormal Yes NO Yes NO NO NO NO Yes 39 M 6 
abnormal abnormalabnormal Yes NO NO NO NO Yes Yes Yes 47 F 7 
abnormal abnormalabnormal Yes NO NO NO NO NO NO Yes 52 M 8 
abnormal abnormalabnormal Yes NO Yes NO NO NO NO Yes 45 M 9 
Normal Normal Normal NO NO NO NO NO NO Yes NO 34 M 10 
Normal Normal Normal NO NO NO NO NO NO Yes Yes 25 M 11 
Normal Normal Normal NO NO NO NO NO NO Yes NO 41 M 12 
Normal Normal Normal NO NO NO NO NO NO NO Yes 45 M 13 
 
PBT= Previous blood transfused 
BD =Blood donate 
OP = Operations 
TA = Tattooing 
IVDU = Intravenous Drug Users. 
AD = Alcoholic Drink  
SC = Sexual Contact 
H = Haemodialysis Machine  
M= Male           F= Female 
 
Chapter five 
Discussion 
 
          In the present study the seroprevalence of viral hepatitis was evaluated 
in sera of patients from different groups , randomly selected in Khartoum area 
and screened by ICT and ELISA (third generation) using recombinant HCV – 
antigens. The liver enzymes levels of these patients were also determined. 
          Out of 380 samples only eleven (2.89%) samples have been found 
positive to HCV – antibodies, when tested by ICT, while 13 (3.4%) samples 
positive by ELISA using recombinant HCV – antigens. A similar study was 
previously done in Juba in Southern Sudan and 3% of the studied populations 
were found positive for HCV – antibodies positive (Mac Carthey et al., 1994). 
Low values of both this study and others suggest that HCV infection is not an 
endemic disease in neither central nor southern Sudan.  
      HCV one step test will only indicate the presence of antibodies to HCV in 
the sample and should not be used as the sole criteria for the diagnosis of 
hepatitis C virus infection. The intensity of the red colour in the test region (T) 
in ICT may vary depending on the concentration of HCV – antibodies present 
in the sample. Therefore any shade of red colour that develops in the test 
region should be considered positive. In contrast in HCV ELISA control 
standards are included in the test and only cut-off value of ≥ 0.8 are 
considered positive.    
      The ELISA detected two positive samples that were negative by ICT test. 
Our study showed a very high concordance between ICT assay and ELISA 
and no statistical significant difference was obtained by the application of 
(T.test) and both assay were sensitive, specific and reliable and the correlation 
between these two systems was 84.6 %.                                                    
          The ELISA test was very sensitive in detecting antibodies to HCV. The 
presence of these antibodies is considered as marker for HCV infection. This 
is in agreement with Chaudhary and Mac Lean (1993). Furthermore, 
Powlotskey et al (1998) reported that weak positive HCV ELISA do not 
needed immunoblot – based confirmatory assay. In contrast the first ELISA 
kits lacked sensitivity as well as specificity (Aach et al., 1991). Bjoro et al 
(1994) reported that samples of HCV RNA were detected by RT – PCR in 
absence of antibodies. Such cases may either from patients with recent 
infection, when the sample was obtained during the seronegative – window 
phase, or from patients with impaired immune response. In this study HCV 
infection has been found high among haemodialysis patients (13.8%) of the 
total haemodialysis samples tested. This is in agreement with Suliman (1995). 
Similarly Fujiyama et al (1995) also reported that the prevalence of HCV – 
infection among dialysis patients is generally matched higher than that among 
healthy blood donors.                 
         Dialysis patients have an increased risk of exposure to parenterally 
transmitted hepatitis virus. Haemodialysis machine and parenteral medicine 
may also pose a risk HCV transmission among HCV – antibodies positive 
patients. The present study is in support of this a Sumiton 69.2% of the 
positive have a history of exposure to haemodialysis machine. Again results 
are in agreement with those obtained by Pereira (1992). However, the dialysis 
process itself and the level of hygienic standard may influence the risk level of 
HCV infection. This may explain the differences found between dialysis 
centres in one country.  Multiple blood transfusions seemed to be an important 
risk factor in the acquisition of HCV infection. Nontheless, screening of blood 
donors for anti – HCV antibodies has been shown to be highly effective in 
preventing transmission HCV (Alter et al., 1995). When parenchymal liver 
cells are damaged aminotransferases leak from the liver into the blood 
resulting in elevated levels of aminotransferases. In our study serum 
aminotransferases level differed significantly between the early and chronic 
phase of HCV infection. They rose in the early phase and fell below the upper 
limit of the normal range in the chronic phase. This probably points an 
indication of an active inflammation of the liver in the early phase with 
normalization of liver function, as measured by ALT levels at the end of the 
follow – up period. This is an agreement with Lau et al (1993), who reported 
that in chronically infected individual elevated aminotransferases level may 
have clinical relevance.                                                                  
           Among the individuals positive for HCV – antibodies 23.1 % of them 
have been exposed to the different surgical operation. These results showed 
that surgical instruments might also be implicated in transmission of infection. 
Tattooing has been considered as a risk factor in the present study and does 
not seen to play any role in transmission of the virus. This was probably due 
to the limited number of samples tested.                                                                                        
       Data presented in this study indicate that the prevalence of HCV infection 
in Sudanese blood donors, multiple transfused and dialysis patients is 
relatively low compared with  records from other countries (Suliman., 1995).                             
 
 
 
 
 
 
 
Conclusion: 
1- Samples when screened by ICT eleven (2.89%) were found positive for 
HCV – antibodies. In contrast when tested by ELISA thirteen (3.4%) 
samples were positive for HCV – antibodies. 
2- In comparison between ICT and ELISA we found a very high 
concordance between ICT and ELISA (correlation 84.6%). 
3-   No significant difference was obtained by application of (T.test), the 
statistical results showed no significant difference between ICT and 
ELISA. 
4-  High incidence of HCV – antibodies (12.3%) was found in 
haemodialysis patients and probably haemodialysis machine have a role 
in the transmission of the disease. 
5- Thirteen (3.4%) serum samples with HCV – antibodies were 
investigated to determined ALT, AST and ALP levels.  
6- Samples obtained from blood donors and multitransfused individuals 
showed normal ALT, AST and ALP values. 
7-  Samples obtained from haemodialysis patients showed elevated ALT 
(96.46 ± 58.96), AST (111 ± 66.52) and ALP (160.15 ± 36.21) levels. 
8- In this study haemodialysis machine and probably surgical instruments 
represent a risk factor, but sex and tattooing have no role in 
predisposition to the disease in various groups studied.                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Recommendation: 
* Blood donors must be tested for HCV – antibodies before transfusion to 
recipient.  
* Haemodialysis patients positive to HCV, must be dialysis separately using 
separate machines. 
* Surgical and tattooing instruments must be well sterilized before each 
operation. 
* Isolation of patients with elevated amiontransferases level could be 
beneficial for preventing the dissemination of HCV among haemodialysis 
patients. 
* ICT is as good as ELISA for screening for HCV – antibodies.   
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